Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon‐like peptide‐1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow‐Up Registry
Authors' conclusion
Real-world registry data revealed improved outcomes with longer median GLP-1 RA persistence; ~50% of patients overall achieved HbA1c <7% at 12 months. Persistence was highest with baseline OAD and/or insulin, and tended to increase over the period 2007-2020.
Study context
- Population
- Adults with T2D initiating their first GLP-1 RA, 2007–June 2020, DPV Registry; 55% men, median age 58.7 years, diabetes duration 8.5 years, HbA1c 8.2%5,189 eligible for persistence
- Participants
- 15,111 adults
- Exposure
- GLP-1 RA persistence by antidiabetes therapy at GLP-1 RA initiation: Oral antidiabetic drugs (OAD) vs insulin ± OAD vs lifestyle modification (LM)
- OADn = 2,453
- Insulin ± OADn = 2,204
- LMn = 532
- Outcome
- GLP-1 RA treatment persistence (Kaplan-Meier) in individuals with ≥12 months follow-up
Methodological detailsmulticentre, real-world
- Multicentre
- Real-world
Main finding
As reported in the abstract
Median GLP-1 RA persistence
- Overall median persistence (n = 5189), months
- 11 (95% CI 10-12)
Observational data: associations, not effects.
Further findings
Persistence over time
- Median treatment persistence tended to increase from 2007-2012 to 2017-2020
HbA1c baseline to discontinuation
- Median HbA1c at baseline, % (IQR 7.1-9.8)
- 8.2
- Median HbA1c at discontinuation, % (IQR 6.6-8.7)
- 7.5
- Greater decrease with persistence >12 months vs ≤12 months
Treatment after discontinuation
- Predominantly switched to insulin (if not already using) or DPP-4i
Original publication
Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon‐like peptide‐1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow‐Up Registry. Diabetes Obes Metab. Published 23 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →